Predictive factors of the response to neoadjuvant chemotherapy include tumor size, pathology subtype, and differentiation as well as expression of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2) and KI67 [5]. This evidence concerns the gene ERBB2 and neoplasm.